

Common Biostatistical Problems
And the Best Practices That Prevent Them

Biostatistics 209
April 19, 2016

John Kornak

Goal: Provide conceptual and practical dos, don'ts, and guiding principles that help in

- Choosing the most meaningful analyses
- Understanding what results of statistical analyses imply for the issues being studied
- Producing clear and fair presentation and interpretation of results


There may be exceptions

Please let me know about additions or disagreements
During lecture, or later (john.kornak@ucsf.edu)

1

2

Optional reference text



Amazon.com link: http://www.amazon.com/p-value-Stories-Actually-Understand-Statistics/dp/0321629302/ref=sr_1_1?ie=UTF8&s=books&qid=1270360017&sr=8-1

3

4

P-values – TRUE or FALSE?

The p-value tells you whether an observed difference, effect, or association is real or not.

P-values – TRUE or FALSE?

If the result is not statistically significant, that proves there is no difference.

P-values – TRUE or FALSE?

If the result is not statistically significant, you have to conclude that there is no difference.

5

6

Problem 1. P-values for establishing negative conclusions

The P-value Fallacy:

The p-value tells you whether an observed difference, effect, or association is real or not.

If the result is not statistically significant, that proves there is no difference.

If the result is not statistically significant, you have to conclude that there is no difference.

-- ALL FALSE

7

How about:

$p > 0.05$ + Power Calculation = No effect

8

How about:

$p > 0.05$ + Power Calculation = No effect

Still no good!

Reasoning via p-values and power is convoluted and unreliable.

9

Power calculations are usually inaccurate. A study of RCTs in 4 top medical journals found more than half used assumed SD's off by enough to produce >2-fold differences in sample size.

CONSORT guidelines: "There is little merit in a post hoc calculation of statistical power using the results of a trial".

Confidence intervals show simply and directly what possibilities are reasonably consistent with the observed data.

10

Additional references:

1958, D.R. Cox: "Power . . . is quite irrelevant in the actual analysis of data."

Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. *Ann Intern Med* 1994; **121**:200-6.

Hoening JM, Heisey DM. The abuse of power: the pervasive fallacy of power calculations for data analysis. *American Statistician*. 2001;**55**:19-34.

Bacchetti P. Current sample size conventions: flaws, harms, and alternatives. *BMC Medicine*, **8**:17, 2010.

11

How about:

$p > 0.05$ + Large N = No effect

$p > 0.05$ + Huge Expense = No effect

$p > 0.05$ + Massive Disappointment = No Effect

12

How about:

$p > 0.05$ + Large N = No effect

$p > 0.05$ + Huge Expense = No effect

$p > 0.05$ + Massive Disappointment = No Effect

Not if contradicted by the CI's!

Confidence intervals show simply and directly what possibilities are reasonably consistent with the observed data.

13

Example: Treatment of an acute infection

Treatment A: 16 deaths in 100

Treatment B: 8 deaths in 100

Odds ratio: 2.2, CI 0.83 to 6.2, $p=0.13$

Estimated risk difference: 8.0%, CI -0.9% to 16.9%

14

Example: Treatment of an acute infection

Treatment A: 16 deaths in 100

Treatment B: 8 deaths in 100

Odds ratio: 2.2, CI 0.83 to 6.2, $p=0.13$

Risk difference: 8.0%, CI -0.9% to 16.9%

“No difference in death rates”

“No **significant** difference in death rates”

“No **statistical** difference in death rates”

“No **statistically significant** difference in death rates”

15

Example: Treatment of an acute infection

Treatment A: 16 deaths in 100

Treatment B: 8 deaths in 100

Odds ratio: 2.2, CI 0.83 to 6.2, $p=0.13$

Risk difference: 8.0%, CI -0.9% to 16.9%

“Our study suggests an important benefit of Treatment B, but this did not reach statistical significance.”

16

NEJM, **354**: 1796-1806, 2006.

“Supplementation with vitamins C and E during pregnancy does not reduce the risk of preeclampsia in nulliparous women, the risk of intrauterine growth restriction, or the risk of death or other serious outcomes in their infants.”

Preeclampsia: RR 1.20 (0.82 – 1.75)

Growth restriction: RR 0.87 (0.66 – 1.16)

Serious outcomes: RR 0.79 (0.61 – 1.02)

Women's Health Initiative study on fat consumption and breast cancer



Invasive Breast Cancer
HR 0.91 (0.83-1.01),
 $p=0.07$

Breast Cancer Mortality
HR 0.77 (0.48-1.22)

From *JAMA* abstract:
“a low-fat dietary pattern did not result in a statistically significant reduction in invasive breast cancer risk”

17

18

Best Practice 1. Provide estimates—with confidence intervals—that directly address the issues of interest.

Often followed (but then ignored when interpreting)

BP2. Ensure that major conclusions reflect the estimates and the uncertainty around them.

BP2a. Never interpret large p-values as establishing negative conclusions.

The estimate is the value most supported by the data

The confidence interval includes values that are not too incompatible with the data

The study provides strong evidence against values outside the CI

19

20

NEJM, **354**: 1889-1900, 2006

Conclusion: “When treated with phototherapy or exchange transfusion, total serum bilirubin levels in the range included in this study were not associated with adverse neurodevelopmental outcomes in infants born at or near term.”

Support: “on most tests, 95 percent confidence intervals excluded a 3-point (0.2 SD) decrease in adjusted scores in the hyperbilirubinemia group.”

21

What if results are less conclusive?

Growth restriction: RR 0.87 (0.66 – 1.16)

Serious outcomes: RR 0.79 (0.61 – 1.02)

“Our results suggest that Vitamin C and E supplementation may substantially reduce the risk of growth restriction and the risk of death or other serious outcomes in the infant, but confidence intervals were too wide to rule out the possibility of no effect.”

22

But then the paper probably won’t end up in *NEJM*!

The “elephant in the room” when it comes to conflict of interest:

- We are all under pressure to make our papers seem as interesting as possible.

The p-value fallacy can help make “negative” studies seem more conclusive and interesting.

Be vigilant (and be honest)!

23

BP3. Discuss the implications of your findings for what may be true in general. Do not focus on “statistical significance” as if it were an end in itself.

24

WHI conclusion:

“a low-fat dietary pattern **did not result in a statistically significant reduction** in invasive breast cancer risk ... However, the nonsignificant trends ... indicate that longer, planned, nonintervention follow-up may yield a **more definitive comparison.**”

Newsweek followup article:

“The conclusion of the breast-cancer study—that a low-fat diet **did not lower** risk—was fairly nuanced. It suggested that if the women were followed for a longer time, there might be **more of an effect.**”

25

Easy to slip into relying on “p>” reasoning

- Yes or No reasoning more natural
- Focus on p-values engrained in research culture
- Real level of uncertainty often inconveniently large, which can make results seem less interesting

Be vigilant

- Double-check all negative interpretations
- Examine estimates, confidence intervals

26

How to check negative interpretations:


Perform searches for words “no” and “not”

Check each negative interpretation found

- Is there an estimate and CI supporting this?
- What if the estimate were exactly right?
- What if the upper confidence bound were true?
- What if the lower confidence bound were true?


Additional searches: “failed”, “lack”, “absence”, “disappeared”, “only”, “rather”, “neither”, “none”

27




We found strong evidence against any substantial harm or benefit.

28



Suggestion of substantial benefit

May be no effect (not statistically significant)




Strong evidence of benefit (statistically significant)


Substantial benefit appears likely, but CI too wide to rule out clinically unimportant benefit

29

30



Strong evidence of substantial clinical benefit



No conclusions possible due to very wide CI

Also see [online resource](http://ctspedia.org/do/view/CTSpedia/ResultsInterpretation)

<http://ctspedia.org/do/view/CTSpedia/ResultsInterpretation>

31

32

Example from a typical collaboration:

First draft text:

“There were no statistically significant effects of DHEA on lean body mass, fat mass or bone density.”

Final wording:

“Estimated effects of DHEA on lean body mass, fat mass, and bone density were small, but the confidence intervals around them were too wide to rule out effects large enough to be important.”

33

Are large p-values good for anything?

“Due diligence” situations

Checking for possible assumption violations when little suspicion

Just need to state that you checked and nothing jumped out; don’t need to prove that no violation was possible:

“We note that the confidence intervals were not narrow enough to rule out potentially important interactions, but in the absence of strong evidence for such interactions we focus on the simpler models without them.”

34

Problem 2. Misleading and vague phrasing

We failed to detect ...

Our results do not support ...

We found no evidence for ...

Our data did not confirm ...

“There is no scientific evidence that BSE [Mad Cow Disease] can be transmitted to humans or that eating beef causes it in humans.”

-- British Prime Minister John Major, 1995

35

BP4. State what you did find or learn, not what you didn’t.

This prevents deception, but also can make statements clearer and stronger.

Oddly, investigators often understate their conclusions using weak phrasing.

36

FRAM, nationwide study of fat abnormalities in persons with HIV

Peripheral fat loss association with central fat gain, OR: 0.71, CI: 0.47 to 1.06, P = 0.10.

First draft: “our results do not support the existence of a single syndrome with reciprocal findings.”

Final: “We found evidence against any reciprocal increase in VAT in HIV-infected persons with peripheral lipoatrophy”

37

Safety of cannabinoids in persons with treated HIV

Marijuana effect on $\log_{10}$ VL: -0.06 (-0.26 to 0.13)
Dronabinol: -0.07 (-0.24 to 0.06)

First draft: “Overall there was no evidence that cannabinoids increased HIV RNA levels over the 21-day study period.”

Final: “This study provides evidence that short-term use of cannabinoids, either oral or smoked, does not substantially elevate viral load in individuals with HIV infection.”

38

Problem 3. Speculation about low power

“There were departures from the design assumptions that likely reduced study power.

...

“If the WHI design assumptions are revised to take into account these departures [less dietary fat reduction], projections are that breast cancer incidence in the intervention group would be 8% to 9% lower than in the comparison group [and] the trial would be somewhat underpowered (projected power of approximately 60%) to detect a statistically significant difference, which is consistent with the observed results.”

39

What are they trying to say?

There might be a 9% reduction in risk. We could have missed it because power was only 60%.

But estimated HR = 0.91, so of course a 9% reduction is possible. It's what they actually saw!

BP2. Ensure that major conclusions reflect the estimates and the uncertainty around them.

40

Problem 4. Exclusive reliance on intent-to-treat analysis

‘Negative’ study of vitamin E in diabetics (*JAMA* 2005)

“To reduce bias, we included continuing followup from those who declined active participation in the study extension and stopped taking the study medication.”

But ITT produces underestimates of actual biological effects: it is biased toward no effect.

41

WHI: Estimate of effect if adherent to low-fat diet:

Breast cancer HR 0.85 (0.71 – 1.02)

Use of more stringent adherence definition “leads to even smaller HR estimates and to 95% CIs that exclude 1.”

42

BP5. Learn as much as you can from your data.

BP5a. Also consider per-protocol analyses, especially if:

- Interest in biological issues
- Double-blinded treatment

BP5b. Consider advanced methods to estimate causal effects.

43

Problem 5. Reliance on omnibus tests

Problem 6. Overuse of multiple comparisons adjustments

Omnibus tests (like ANOVA)

- check for any one or more of a large number of possible departures from a global null hypothesis (nothing is happening anywhere)
- inherently focused only on p-values (Problem 1)
- diffuse, so weaker for specific issues

Multiple comparisons adjustments

- each result detracts from the other

44

Investigator's panicked inquiry:

Animal experiment that included

- a condition that just confirms that the experiment was done correctly
- some places where different conditions should be similar
- some conditions that should differ

Saw expected results in pairwise comparisons, but "ANOVA says that there is nothing happening"

45

Reviewer's comment on a study examining effects of 4 different administration routes

"Repeated measures analysis of variance should be completed. **Only if the time-by-treatment interaction is significant**, should time-specific comparisons be made. Then multiple comparison procedures, such as Tukey's test, should be used rather than repeated t tests."

This would treat $p > 0.05$ on the unfocused omnibus test of time-by-treatment interaction as a reliable indicator that no important differences are present—**Problem 1**.

46

Study of biology of morphine addiction:

Very complex design involving:

- two different receptors
- antagonists
- different brain regions with and w/o certain receptor
- systemic vs local administration

Results of many pairwise comparisons fit a biologically coherent pattern.

47

Reviewer: "The statistical analyses are naïve. The authors compute what appear to be literally dozens of t-tests without any adjustment to the alpha level --- indeed **the probability of obtaining false positives grows with the number of such tests computed**. The authors should have conducted ANOVAs followed by the appropriate post-hoc tests. Their decision to simply compute t-tests on all possible combinations of means is statistically unacceptable."

But the probability of obtaining multiple positive results exactly where expected and negative results exactly where expected does not grow; it becomes vanishingly small.

48

BP6. Base interpretations on a synthesis of statistical results with scientific considerations.

BP6a. Rely on scientific considerations to guard against overinterpretation of isolated findings with $p < 0.05$. (This is usually preferable to formal multiple comparisons adjustment.)

BP6b. Acknowledge the desirability of independent replication, particularly for unexpected findings.

BP7. Choose accuracy over conservatism whenever possible.

49

Problem 7. Entangled outcomes and predictors

Body mass index as a “predictor” of central fat model:

$$\begin{aligned}\text{central} &= \text{peripheral } \beta_1 + \text{BMI } \beta_2 + \varepsilon \\ &= \text{peripheral } \beta_1 + (\text{peripheral} + \text{central}) / \text{height}^2 \beta_2 + \varepsilon\end{aligned}$$

Many people have low peripheral and low central fat

A few (with HIV and not) have low peripheral fat and high central fat

Low peripheral fat + low central fat $\rightarrow$ low BMI

Low central fat “explained” by low BMI in these cases

Association of peripheral fat and central fat therefore determined by rare cases of low peripheral fat and high central fat, causing a spurious association

50

Total time on treatment as a (fixed) predictor of survival time

Can only be treated if alive
(survival time = treated time + untreated time)

Died after 2 days $\rightarrow$ max of 2 days treatment
Treated for 5 years $\rightarrow$ min of 5 years survival

Meaningless association

51

BP 8: Either

- 1) ensure that outcome is not part of the definition of a predictor, and vice versa, or
- 2) be very careful and clear with interpretation

Fixed (e.g. baseline) predictors should be defined without using any information from after the start of followup

Use time-dependent covariates, defined only using measurements up to present

52

Technical problems

Unchecked assumptions

- Always list assumptions, describe checks and results thereof

Ignored dependence and clustering

- e.g., unpaired analysis on paired (before/after) data
- Dr. McCulloch’s lectures deal with more complex levels of clustering and repeated measures

53

Unclear details for time-to-event

- operational definitions – start time, event occurrence, censoring time
- summarize follow up among those censored
- summarize early loss to follow up separately
- how were events ascertained?

Poor summaries

- e.g., mean $\pm$ SD for skewed data – better median/IQR
- SD’s or SE’s? SE’s (or better CI’s) for precision of estimates, whereas SD’s for population variability

54

Showing inadequate or excessive precision

- too little $\Rightarrow$ reader wonders how big exactly
- too much $\Rightarrow$ false impression of precision (naïve)
- p-values 2 significant digits, HR's 2 decimals if < 2.0 and one if ≥ 2.0
- other values – means, SDs etc., balance scientific relevance, clarity and realistic accuracy
- not $p=NS$ or $p>0.1$ – encourages p-value fallacy
- do not show χ^2 , F statistics – nothing over p-value

Poorly scaled predictors

- e.g., don't look at age effects per day... in particular HR's difficult to convert in the reader's head.

55

Terms likely to be misread

- especially “significant” – use “statistically significant”, or if implying more general definition use “important”, “substantial”, or (best) “clinically significant” – if journal insists on “significant” for “statistically significant” try to avoid completely.
- use “relative hazard” or “hazard ratio” for proportional hazards models – NOT “relative risk” – latter used for relative risk modeling of binary outcomes.
- Use “Mann-Whitney” or “Wilcoxon rank-sum” not “Wilcoxon” to avoid confusion with “Wilcoxon signed-rank”.

56

Missing Data

- can cause bias -- depends on why missing
- e.g., those with the riskiest behavior may be more inclined to skip questions about risk factors.

Prevention is best, otherwise

- clearly disclose how much
- give reasons when known
- assess differences in other variables of non-responders
- perform sensitivity analyses – compare different assumptions for the missing data. Do conclusions change?

57

- consider advanced methods, e.g., Stata can perform *multiple imputation* (see the *mi* command and <http://www.ats.ucla.edu/stat/stata/Library/ice.htm>). You will likely need help from a statistician to use such approaches.
- when comparing single and multiple predictor model results, use same set of observations.

58

Homework

Examine the two assigned papers

Look for:

- use of best practices, other strengths
- problems
- missed opportunities for using best practices

Think about what would have been better and the practical or scientific consequences

We will discuss these on Thursday

59

Written Homework

Due **before class THIS Thursday 4/21**

Choose one paper and

describe occurrence of one of the problems. Quote text or pinpoint specific results or passages to clearly identify what you discuss. What should have been done to avoid the problem?

60

Heisler M, Faul JD, Hayward RA, Langa KM, Blaum C, Weir D. Mechanisms for Racial and Ethnic Disparities in Glycemic Control in Middle-aged and Older Americans in the Health and Retirement Study. *Arch Intern Med* 2007; **167**:1853-1860.

Homsy J, Bunnell R, Moore D, King R, Malamba S, et al. Reproductive Intentions and Outcomes among Women on Antiretroviral Therapy in Rural Uganda: A Prospective Cohort Study. *PLoS ONE* 2009; **4**(1): e4149.

61

Summary of Biostatistical Best Practices

BP1. Provide estimates—with confidence intervals—that directly address the issues of interest.

BP2. Ensure that major conclusions reflect the estimates and the uncertainty around them.

BP2a. Never interpret large p-values as establishing negative conclusions.

BP3. Discuss the implications of your findings for what may be true in general. Do not focus on “statistical significance” as if it were an end in itself.

BP4. State what you did find or learn, not what you didn’t.

63

BP7. Choose accuracy over conservatism whenever possible.

BP8. Ensure outcome is not part of the definition of a predictor, or (if you must) be very careful and clear with interpretation.

65

Summary of Problems

Problem 1. P-values for establishing negative conclusions

Problem 2. Misleading and vague phrasing

Problem 3. Speculation about low power

Problem 4. Exclusive reliance on intent-to-treat analysis

Problem 5. Reliance on omnibus tests

Problem 6. Overuse of multiple comparisons adjustments

Problem 7. Entangled outcomes and predictors

62

Summary of Biostatistical Best Practices

BP5. Learn as much as you can from your data.

BP5a. Also consider per-protocol analyses, especially if:

- Interest in biological issues
- Double-blinded treatment

BP6. Base interpretations on a synthesis of statistical results with scientific considerations.

BP6a. Rely on scientific considerations to guard against overinterpretation of findings with $p < 0.05$.

BP6b. Acknowledge the desirability of independent replication, particularly for unexpected findings.

64

Specific exercise for written projects:

Perform searches for words “no” and “not”

Check each sentence found

- Is there an estimate and CI supporting this?
- What if the point estimate were exactly right?
- What if the upper confidence bound were true?
- What if the lower confidence bound were true?

Additional searches: “failed”, “lack”, “absence”, “disappeared”, “only”, “rather”, “neither”, “none”

66

Also for your written projects

Try to avoid the other problems and follow the best practices

(Or be clear on why your case is an exception)

Take advantage of the faculty help that is available